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BORTEZOMIB AND HIGH DOSE MELPHALAN FOLLOWED BY AUTOLO-
GOUS STEM CELL TRANSPLANTATION (B-HDM/SCT) FOR THE TREAT-
MENT OF AL AMYLOIDOSIS: RESULTS OF A FEASIBILITY STUDY
Sanchorawala, V., Yanarella, L., Quillen, K., Sloan, J.M., Andrea, N.T.,
Finn, K.T., Seldin, D.C. Boston University Medical Center, Boston, MA
Aggressive treatment of AL amyloidosis with high dose melphalan
and autologous stem cell transplant (HDM/SCT) is effective in in-
ducing hematologic remission and clinical improvement. We have
observed in  500 patients treated with HDM/SCT that achieve-
ment of a hematologic complete response (CR) is a critical determi-
nant of clinical improvement and survival. A synergistic effect
between bortezomib (B) andmelphalan has been demonstrated in vi-
tro and in vivo. Thus, the combination of B and HDM is a logical
approach to study. Because of the importance of hematologic CR
in treatment outcome, we conducted a feasibility study to determine
whether addition of B to HDM/SCT would be tolerable and would
increase hematologic CR rates. Eligibility for entry into the trial re-
quired diagnosis of AL amyloidosis, age. 18 years, and adequate
performance status (SWOG# 2) and cardiopulmonary function
(LVEF. 45%, DLCO. 50%). Peripheral blood stem cells were
collected following G-CSF mobilization, with minimum yields of
2.5  106 CD34+ cells/kg required for participation in the trial. B
was administered at 1 mg/m2 on D -6, D -3, D +1, and D +4 and
HDM at 140-200 mg/m2 in two divided doses on D -2 and D -1.
From 10/2008 to 10/2009, 9 patients were enrolled (median age
53, range 46-68; median number of involved organs 2, range 1-4).
Of the 9 patients enrolled, 1 patient was removed from the protocol
because of cardiac arrhythmia during stem cell mobilization and col-
lection phase that precluded treatment with HDM/SCT. Of the 8
patients who received B-HDM/SCT, there was no treatment-related
mortality within 100 days of SCT and there were no unexpected he-
matologic or non-hematologic toxicities associated with addition of
B to HDM/SCT. The median times to neutrophil and platelet en-
graftment was D +10 and D +14 after SCT, respectively. Of 8 pa-
tients evaluable for early responses, normalization of serum free
light chain levels and ratio occurred in 7 of 8 (88%) by D +14 and
one patient achieved a 45% reduction in serum free light chain con-
centration at D +14. Of the initial 2 patients with longer follow-up,
both have achieved a hematologic CR at 6 and 9months following B-
HDM/SCT. Follow-up is ongoing and hematologic responses ap-
pear to be well-maintained. Thus, this pilot study demonstrates
that B-HDM/SCT is tolerable for selected patients with AL amy-
loidosis and leads to a high rate of hematologic responses.127
TRANSPLANT ASSOCIATED-THROMBOTIC MICROANGIOPATHY (TA-
TMA) IN PEDIATRIC NEUROBLASTOMA (NB) PATIENTS UNDERGOING
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): A CASE-CONTROL
STUDY IDENTIFYING EARLY CLINICAL MARKERS OF DISEASE
Laskin, B.L.1, Goebel, J.1, Davies, S.M.2, Bleesing, J.J.2, Mehta, P.A.2,
Filipovich, A.H.2, Khoury, J.C.3, Paff, Z.N.2, Jodele, S.2 1Cincinnati
Children’s Hospital Medical Center (CCHMC), OH; 2Cincinnati Child-
ren’s Hospital Medical Center, OH; 3Cincinnati Children’s Hospital Med-
ical Center, OH
Patients (pts) undergoing ASCT for NB present a unique popula-
tion to studyTA-TMAdue to their standardized chemotherapy, lack
of graft-versus host disease prophylaxis, and subsequent exposure to
radiation and cis-retinoic acid (cisRA).We performed a retrospective
case-control study of TA-TMA in NB pts who underwent ASCT at
CCHMC in the past 5 years to identify strategies for early rigorous
diagnosis. Twenty pts with high risk NB were treated with melpha-
lan, carboplatin, and etoposide followed by ASCT. Six pts were di-
agnosed with TA-TMA (4 within 25 days of ASCT) presenting
with microangiopathic hemolytic anemia, elevated lactate dehydro-genase, thrombocytopenia, hypertension (HTN), and acute kidney
injury (3 confirmedwith renal biopsy). Adenovirus, cytomegalovirus,
and influenza B were potential triggers of TA-TMA (n5 2). The 14
pts without TA-TMA served as controls. Clinical and laboratory
data were obtained for the first 30 days pre- and post-ASCT. Blood
pressure (BP) index was calculated as BP/95th percentiles for age and
height (value .15HTN). No pt had HTN pre-ASCT. Fischer’s
exact test, Wilcoxon rank sum and generalized linear models were
used for analysis. Results are shown in the Table. Proteinuria, hema-
turia, and schistocytes on blood smear were significantly associated
with TA-TMA, while blood and platelet transfusions were not.
HTN requiring therapy proved to be a very significant indicator of
TA-TMA and was identified within days of ASCT. Although serum
creatinine (SCr) did not differ significantly between groups, pts with
TA-TMA had an average 60% decrease in renal function from base-
line by nuclear glomerular filtration rate (nucGFR) post ASCT,
compared to a 30% decrease in those without TA-TMA. TA-
TMA therapy included steroids, plasmapheresis, and rituximab.
There was no TA-TMA-related mortality, but significant complica-
tions included progression to chronic dialysis (n5 1) and severe pol-
yserositis (n5 2). None of the pts with TA-TMA were able to
complete cisRA therapy. Overall, we found a 30% prevalence of
TA-TMA in transplanted NB pts. The most significant indicator
of TA-TMA was HTN. Our data are limited by their retrospective
nature and small sample size.We suggest that careful BP observation
and urinalysis monitoring will assist in the early diagnosis of TA-
TMA, while SCr measurements are of limited value. Prospective
studies are needed to confirm these results as early diagnosis and
treatment may eventually help to improve outcome.
Indicators of TA-TMA during first month post-ASCT
TA-TMA No TA-TMA
Variable (n5 6) (n5 14) P-valueProteinuria 4 (67%) 2 (15%) 0.046
Hematuria 4 (67%) 1 (8%) 0.02
Schistocytes 4 (67%) 1 (8%) 0.02
Pre-ASCT NucGFR 152.06 12.9 145.66 10.9 0.64
Post-ASCT NucGFR* 61.06 8.8 103.16 6.2 0.002
SCr (mg/dL) 0.546 0.04 0.496 0.02 0.28
Systolic BP (mm Hg) 112.26 2.5 102.26 1.6 0.004
Diastolic BP (mm Hg) 66.76 2.2 55.46 1.5 0.001
Systolic Index 1.026 0.02 0.926 0.02 0.002
Diastolic Index 0.996 0.04 0.816 0.02 0.001
Pts requiring HTN therapy 5 (83%) 3 (21%) 0.006Data n (%) or mean6 standard error. *NucGFR (ml/min/1.73 m2) done
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IS LOW DOSE CYCLOPHOSPHAMIDE PLUS G-CSF MOBLIZATION AS EF-
FECTIVE AS MOZOBIL (PLERIXAFOR) PLUS G-CSF IN MULTIPLE MYE-
LOMA (MM) PATIENTS ELIGIBLE FOR TANDEM TRANSPLANT?
Karanes, C.1, Dagis, A.3, Wang, S.4, Krishnan, A.1, Sahebi, F.1,
Popplewell, L.1, Parker, P.1, Forman, S.1, Palmer, J.3, Kogut, N.1,
Somlo, G.2 1City of Hope, Duarte, CA; 2City of Hope, Duarte, CA;
3City of Hope, Duarte, CA; 4City of Hope, Duarte, CA
Introduction: A recent study showed 71.6% of patients who re-
ceived plerixafor plus G-CSF collected .6  106 CD34+ cells/kg
in# 2 apheresis procedures when compared to placebo plus G-
CSF.We analyzed retrospectively two tandem autologous transplant
protocols where cyclophosphamide plus G-CSF (Cy-G) was used as
mobilization therapy.
Methods: From 08/1999 to 06/2009, 120 MM patients were en-
rolled. Patients received 1.5 g/m2 of Cy followed byG-CSF. Patients
underwent consecutive leukapheresis starting on day 10 and contin-
ued until a minimum of 4x 106 CD34+/kg was collected and 6 106
CD34+/kg when possible.
Results:Median days to reach 4x 106 CD34+/kg was 1 (1-16) and for
6 106 CD34+/kg was 2 (1-16). Median days of total apheresis was 3
